Influence on diabetes mellitus

Investigations were carried out on mice, who 7 days after being induced with diabetes mellitus were fed for 14 days with 50, 100 or 200 mg of Megamin Activ per mouse. The result was restoration of body weight to an even slightly greater degree than in the control group, as well as improved glucose tolerance, which normalised after only 2 hours following injection of 1 g of glucose per kilogram of body weight. Not one of the doses studied produced a hypoglycaemic reaction.

Results in vivo

Mice were inoculated with melanoma B16 cells, and were then given Megamin Activ twice a day orally for 5 days. Observation of tumour volume confirmed that Megamin Activ reduced tumour volume in mice.

Results in vivo

Studies on tumour patients in the USA

Testing was carried out on 5 patients (2 female, 3 male) between the ages of 35 and 77, all in critical condition. One female patient was diagnosed with hypernephroma lat.sin. The patient refused surgery and chemotherapy, and was in very poor physical and psychological condition. She began taking Megamin Activ and after a short period of time her overall condition significantly improved, she gained weight and began to walk (which she had previously been unable to do). Another female patient was diagnosed with cervical cancer with metastasis in the bones.

Studies on tumour patients in the USA

Testing was carried out on 5 patients (2 female, 3 male) between the ages of 35 and 77, all in critical condition. One female patient was diagnosed with hypernephroma lat.sin. The patient refused surgery and chemotherapy, and was in very poor physical and psychological condition. She began taking Megamin Activ and after a short period of time her overall condition significantly improved, she gained weight and began to walk (which she had previously been unable to do). Another female patient was diagnosed with cervical cancer with metastasis in the bones. After two rounds of chemotherapy she began taking Megamin Activ in capsule and powder form, which resulted in a 50% reduction in the tumour and significant improvement in overall condition. The male patients were suffering from lymphosarcoma femoris l.sin, multiplemetastases, pancreatic cancer and intestinal cancer with metastasis. All began taking Megamin Activ in capsule and powder form in large doses (24-40 capsules) which quickly resulte in significant improvement in overall condition.

Studies on tumour patients in Croatia

Conclusion

With a series of results documenting the positive effects of tribomechanically activated zeolite in a series of anecdotal cases involving various health problems in people, scientific research was begun in 1997 to investigate the potential effects on biological systems. The scientific investigations included testing the acute, subacute and chronic toxicity of Megamin Activ, effects of Megamin Activ on various canine tumours, Megamin Activ influence on cancer (in vivo and in vitro), on diabetes mellitus, in liver disease, the possibilities for use of Megamin Activ in the treatment of wounds, in neurodegenerative diseases, in transitory hypogamaglobulonaemia, as well as testing its antioxidative effects. Results of investigations so far, as well as use in practice, indicate the necessity to continue to the research, with a multicentre approach and with various goals. It has definitely been confirmed that Megamin Activ is a very effective oxidoreductive preparation, and probably the most powerful antioxidant in the world that is taken orally. Therefore, in this phase of the research the conclusion can already be drawn that its use as a roborant in adjuvant therapies, as well as for prophylaxis and improvement of immunity in healthy people is to be recommended.